Imitex has created a substantial suite of intellectual property regarding the activation of MEF2. This asset draws on more than 20 years of experience combined with cutting-edge AI and quantum drug discovery tools to identify and develop new therapeutics.
The articles below provide insights into Professor McGee’s research – and related studies – that validate MEF2 as a high-priority target for therapeutic development.
Our MEF2 research has been independently validated by the Molecular Transducers of Physical Activity (MoTrPAC) consortium in Nature (2024) – reinforcing MEF2's critical role in exercise adaptation.